CompletedPhase 2NCT02354261

Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

Studying Gorlin syndrome

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: HedgePath Pharmaceuticals, Inc.
Principal Investigator: James Solomon, MD, PhD
Ameriderm Clinical Research
Intervention: SUBA-Itraconazole(drug)
Enrollment: 38 enrolled
Eligibility: 18 years · All sexes
Timeline: 2015 – 2019

Study locations (5)

Dermatology Specialists, Inc, Oceanside, California, United States
Ameriderm Research, Ormond Beach, Florida, United States
Grekin Skin Institute, Warren, Michigan, United States
Stony Brook University, East Setauket, New York, United States
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02354261 on ClinicalTrials.gov

Other trials for Gorlin syndrome

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT06050122
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Sol-Gel Technologies, Ltd.

See all trials for Gorlin syndrome →

← Back to all trials